8-K: InMed Pharmaceuticals Announces Fiscal Year 2024 Results and Provides Business Update

InMed Pharmaceuticals reported a revenue increase of 11% for fiscal year 2024, alongside advancements in their Alzheimer's and AMD drug programs.

Summary

• InMed Pharmaceuticals reported its financial results for the fiscal year ending June 30, 2024, and provided a business update.
• The company's revenue reached $4.6 million, an 11% increase compared to the previous fiscal year.
• InMed experienced a net loss of $7.7 million, slightly improved from the $7.9 million loss in the previous year.
• The company's cash, cash equivalents, and short-term investments totaled $6.6 million as of June 30, 2024.
• Research and development expenses were $3.8 million, a slight increase from $3.7 million in the previous year.
• General and administrative expenses decreased to $5.3 million from $5.8 million the previous year.
• The company is advancing its INM-901 program for Alzheimer's disease and INM-089 program for Age-related Macular Degeneration (AMD).
• BayMedica, InMed's commercial subsidiary, also contributed $4.6 million in revenue, reflecting an 11% increase year-over-year.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The revenue growth and progress in drug development are positive, but the net loss and limited cash runway are concerning. Overall, the sentiment is cautiously optimistic.

Positives

• Revenue increased by 11% to $4.6 million for the fiscal year 2024.
• The net loss decreased slightly from $7.9 million to $7.7 million year-over-year.
• The INM-901 program is showing promising results in preclinical studies, targeting multiple pathways associated with Alzheimer's disease.
• The INM-089 program has demonstrated neuroprotective effects in preclinical studies for the treatment of dry AMD.
• Three new U.S. patents were issued, enhancing the company's intellectual property.
• General and administrative expenses decreased from $5.8 million to $5.3 million.

Negatives

• The company experienced a net loss of $7.7 million for the fiscal year 2024.
• Research and development expenses increased slightly to $3.8 million.
• The company's cash position decreased to $6.6 million from $8.9 million the previous year.

Risks

• The company's cash is expected to be sufficient to fund operations only until the end of the fourth quarter of calendar year 2024.
• The company's future revenue is dependent on distributor order patterns.
• The company's research and development expenses are expected to increase significantly in future periods.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.

Future Outlook

The company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure requirements to the end of the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues as well as the level and timing of the Company's operating expenses. The company also anticipates increased research and development expenses as they continue to implement their business strategy.

Management Comments

• Eric A. Adams, InMed Chief Executive Officer, stated that they made significant progress in their pharmaceutical pipeline, advancing two preclinical programs targeting Alzheimer's disease and dry AMD.
• He also noted that the Alzheimers treatment landscape has shifted significantly, underscoring the need for innovative, disease-modifying therapies.

Industry Context

The company is operating in the pharmaceutical sector, specifically focusing on developing treatments for Alzheimer's disease and Age-related Macular Degeneration (AMD), which are areas of high unmet medical need. The company is also involved in the rare cannabinoid market through its subsidiary BayMedica.

Comparison to Industry Standards

• InMed's revenue growth of 11% is a positive sign, but it is important to compare this to other pharmaceutical companies in the same stage of development.
• The net loss of $7.7 million is typical for a company in the research and development phase, but it is important to monitor the burn rate and cash runway.
• The company's focus on small molecule drug candidates targeting CB1/CB2 receptors is a unique approach that could differentiate them from competitors.
• Companies like Biogen and Eli Lilly are also developing Alzheimer's treatments, but InMed's approach is different, focusing on multiple biological pathways.
• In the AMD space, companies like Regeneron and Roche are developing treatments, but InMed's focus on dry AMD and geographic atrophy is a specific niche.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and progress in drug development, but concerned about the net loss and cash position.
• Employees may be motivated by the company's progress, but also aware of the financial challenges.
• Customers of BayMedica may benefit from the company's focus on high-margin products.
• Suppliers may be impacted by the company's financial situation and potential need for cost-cutting measures.
• Creditors may be concerned about the company's cash position and ability to meet its obligations.

Next Steps

• InMed will continue to accelerate the development of its Alzheimer's program, with additional molecular analysis of a preclinical long-term dosing study underway.
• The company will continue the development of the chemistry, manufacturing, and controls (CMC) for both the drug substance and the drug product formulation for INM-901.
• GLP studies are in the planning stages to support an IND submission for INM-901.
• InMed will continue to assess potential partnership opportunities for the advancement of INM-755.
• The company will continue to focus on products that contribute highest margins within BayMedica.

Key Dates

Keywords

Alzheimer's disease, Age-related Macular Degeneration, AMD, INM-901, INM-089, BayMedica, cannabinoids, pharmaceuticals, drug development, net loss, revenue, patents, preclinical studies